Literature DB >> 9152968

Treatment of aggressive non-Hodgkin's lymphoma in adults--are we doing any better?

H Hagberg1, E Kimby.   

Abstract

Great improvement in the treatment of patients with aggressive non-Hodgkin's lymphoma (NHL) has been obtained with the introduction of new combination chemotherapy regimens in the 1970s. The hope that there would be further improvement has waned during recent years due to the fact that some controlled studies did not reveal any better results using the new more intensive treatment regimens. This is the reason for the question: are we doing any better?

Entities:  

Mesh：

Year:  1996        PMID： 9152968     DOI： 10.1007/bf02990930

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  59 in total

1.  Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.

Authors:  L I Gordon; D Harrington; J Andersen; J Colgan; J Glick; R Neiman; R Mann; G D Resnick; M Barcos; A Gottlieb
Journal:  N Engl J Med       Date:  1992-11-05       Impact factor: 91.245

2.  Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy.

Authors:  A Avilés; S Delgado; H Ruiz; A de la Torre; R Guzman; A Talavera
Journal:  Eur J Cancer B Oral Oncol       Date:  1996-01

3.  COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma.

Authors:  D B Boyd; M Coleman; S W Papish; A Topilow; S K Kopel; B Bernhardt; J C Files; S Schwartz; M Gaynor; D McDermott
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

4.  Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.

Authors:  U Vitolo; S Cortellazzo; A M Liberati; R Freilone; M Falda; M Bertini; B Botto; S Cinieri; A Levis; F Locatelli; E Lovisone; F Marmont; M Pizzuti; A Rossi; P Viero; T Barbui; F Grignani; L Resegotti
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 5.  The effect of combined modality therapy on local control and survival.

Authors:  V T DeVita; M Lippman; S M Hubbard; D C Ihde; S A Rosenberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

6.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Authors:  W S Velasquez; P McLaughlin; S Tucker; F B Hagemeister; F Swan; M A Rodriguez; J Romaguera; E Rubenstein; F Cabanillas
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

7.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.

Authors:  H H Gerhartz; M Engelhard; P Meusers; G Brittinger; W Wilmanns; G Schlimok; P Mueller; D Huhn; R Musch; W Siegert
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

8.  High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma.

Authors:  T Philip; O Hartmann; P Biron; J Y Cahn; F Pein; P Bordigoni; G Souillet; M Gartner; C Lasset; F Chauvin
Journal:  J Clin Oncol       Date:  1988-07       Impact factor: 44.544

9.  Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma.

Authors:  J M Connors; P Klimo; R N Fairey; N Voss
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

10.  A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.